39919-70-5 | Page 2 of 3 | Pyridine-derivatives

Jung, Hyeon Cheol et al. published their patent in 2011 |CAS: 39919-70-5

The Article related to organic electroluminescent device electron injection transport aromatic, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Spectrometers and Optical Apparatus and other aspects.Product Details of 39919-70-5

On June 15, 2011, Jung, Hyeon Cheol; Yoo, In Seon; Lee, Jeong Ae; Park, Seong Hui published a patent.Product Details of 39919-70-5 The title of the patent was Organic electroluminescent device having novel electron transport/injection materials comprising aromatic compound. And the patent contained the following:

The title organic electroluminescent device comprises stacked anode, hole injection layer, hole transport layer, host + dopant layer, electron transport layer, electron injection layer, and cathode. The compound shown in chem. formula I is used in the electron transport layer and the electron injection layer, wherein, R1, R2 and R3 are the same or not, and are substituted or unsubstituted aromatic groups, heterocyclic groups or aliphatic groups. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Product Details of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Cha, Sun Uk et al. published their patent in 2014 |CAS: 39919-70-5

The Article related to asym pyrene heteroaryl amine electroluminescent dopant flat panel display, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Luminescence and other aspects.Formula: C9H14N2

On October 15, 2014, Cha, Sun Uk; Jung, Gyeong Seok; Park, Seok Bae; Kim, Hui Dae; Lee, Yu Rim; Song, Ju Man; Hwang, Mun Chan published a patent.Formula: C9H14N2 The title of the patent was Asymmetric pyrene derivative comprising heteroaryl amine as electroluminescent dopant for organic light-emitting device. And the patent contained the following:

The present invention relates to an asym. pyrene derivative comprising heteroaryl amine, and an organic light-emitting device comprising the same. The asym. pyrene derivative comprising heteroaryl amine is represented by formula I or II (Py = substituted or unsubstituted pyridinyl; Het1-Het3 = heterogeneous atom selected from oxygen, nitrogen, sulfur and silicon, C2-C50 heteroaryl group; Z = hydrogen, deuterium, C1-C30 alkyl group, C5-C50 aryl group, C2-C30 alkenyl group, C2-C20 alkynyl group, C3-C30 cycloalkyl group, C5-C30 cycloalkenyl group, etc.; m = integer of 1-8 for formula I and 1-9 for formula II, where the substitution is selected from deuterium, cyano group, halogen, hydroxyl group, nitro group, C1-C24 alkyl group, etc.). The organic light-emitting device comprises: a first electrode; a second electrode placed opposite to the first electrode; and an organic layer placed between the first and second electrodes, where the organic layer includes an organic light-emitting compound i.e. asym. pyrene derivative The organic layer is selected from hole injection layer having hole injection function, hole transport layer having hole transport function, functional layer, light-emitting layer, electron transport layer, and electron injection layer. According to the present invention, the asym. pyrene derivative has excellent luminous efficiency and high-color purity, and is utilized in the organic light-emitting device such as flat panel display device, flexible display device, monochromatic or white flexible lighting device, etc. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Formula: C9H14N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Cha, Sun Uk et al. published their patent in 2014 |CAS: 39919-70-5

The Article related to amine group asym pyrene derivative pyridinyl electroluminescent dopant oled, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Luminescence and other aspects.Safety of 6-(tert-Butyl)pyridin-3-amine

On October 15, 2014, Cha, Sun Uk; Jung, Gyeong Seok; Park, Seok Bae; Kim, Hui Dae; Lee, Yu Rim; Song, Ju Man; Hwang, Mun Chan published a patent.Safety of 6-(tert-Butyl)pyridin-3-amine The title of the patent was Amine group substituted asymmetric pyrene derivative comprising pyridinyl group as electroluminescent dopant and/or organic semiconductor materials for organic light-emitting device. And the patent contained the following:

The present invention relates to an amine group substituted asym. pyrene derivative, and an organic light-emitting device comprising the same. The amine group substituted asym. pyrene derivative comprising pyridinyl group is represented by formula I (Py1, Py2 = substituted or unsubstituted pyridinyl group; Ar1, Ar2 = substituted or unsubstituted C1-C30 alkyl group, substituted or unsubstituted C3-C30 cycloalkyl group, substituted or unsubstituted C5-C50 aryl group, C2-C50 heteroaryl group having one or more substituted or unsubstituted atoms selected from oxygen, nitrogen, sulfur and silicon; Z = hydrogen, deuterium, substituted or unsubstituted C1-C30 alkyl group, substituted or unsubstituted C5-C50 aryl group, substituted or unsubstituted C2-C30 alkenyl group, substituted or unsubstituted C2-C20 alkynyl group, substituted or unsubstituted C3-C30 cycloalkyl group, substituted or unsubstituted C5-C30 cycloalkenyl group, etc.; and m = integer of 1-8, where the substituted or unsubstituted substitution is selected from deuterium, cyano group, halogen, hydroxyl group, nitro group, C1-C24 alkyl group, etc.). The organic light-emitting device comprises: a first electrode; a second electrode placed opposite to the first electrode; and an organic layer placed between the first and second electrodes, where the organic layer includes an organic light-emitting compound i.e. amine group substituted asym. pyrene derivative The organic layer is selected from hole injection layer having hole injection function, hole transport layer having hole transport function, functional layer, light-emitting layer, electron transport layer, and electron injection layer. According to the present invention, the amine group substituted asym. pyrene derivative has excellent luminous efficiency and high-color purity, and is utilized in the organic light-emitting device for producing full-color display. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Safety of 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Flohr, Alexander et al. published their patent in 2021 |CAS: 39919-70-5

The Article related to isoindolinone preparation cereblon inhibitor gspt1 degrader, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Recommanded Product: 39919-70-5

On April 15, 2021, Flohr, Alexander; Eidam, Olive; Fasching, Bernhard; Meniconi, Mirco; Sadok, Amine; Chopra, Rajesh; Zhuai Wang, Hannah; Caldwell, John Jamieson; Collins, Ian; Ryckmans, Thomas published a patent.Recommanded Product: 39919-70-5 The title of the patent was Isoindolinone compounds as cereblon inhibitors and GSPT1 degraders and their preparation. And the patent contained the following:

Disclosed herein is a compound of formula I or pharmaceutically acceptable salts or stereoisomers thereof. Compounds of formula I wherein X1 is (un)branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl-C3-6 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, etc.; X2 is H, C6-10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 4- to 8-membered heterocycloalkyl, etc.; n is 0, 1 and 2; and pharmaceutically acceptable salts, and stereoisomers thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their cereblon inhibitory activity and GSPT1 degradation activity. From the assay, it was determined that compound II exhibited IC50 value of 1037 nM and a DC50 value of > 300 nM. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Recommanded Product: 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Jung, Hyeon Cheol et al. published their patent in 2011 |CAS: 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Stoessel, Philipp et al. published their patent in 2014 |CAS: 39919-70-5

The Article related to iridium platinum cyclometalated heterocyclic bicyclic complex preparation phosphorescent emitter, electroluminescent device organic platinum iridium cyclometalated complex emitter and other aspects.Electric Literature of 39919-70-5

On February 13, 2014, Stoessel, Philipp; Joosten, Dominik; Breuning, Esther; Kaiser, Joachim published a patent.Electric Literature of 39919-70-5 The title of the patent was Cyclometalated iridium and platinum complexes as phosphorescent emitters for organic electroluminescent devices. And the patent contained the following:

Iridium and platinum complexes with bi- and tridentate cyclometalated ligands [(Cy1-Cy2-Q)mMLn] (1, Cy1, Cy2 = preferably aromatic cycles, condensed with aliphatic bicyclic systems, bound through heteroatom and carbon, resp., preferably, pyridine, quinoline, phenanthridine, azole derivatives, Q = optional donor-containing group, L = auxiliary ligand; preferably, L = acetylacetonato, picolinato), useful as triplet-emitting dopants or additives for light-emitting layers in organic light-emitting devices, preferably short-wave emitters, as green or blue emitters, were prepared by cyclometalation of the corresponding proligands Cy1-Cy2H-Q with properly chosen metal precursors, such as PtCl2, K2PtCl4, PtCl2(DMSO), PtMe2(DMSO)2, PtCl2(NCPh)2, and subsequent ligand substitution for introduction of the auxiliary ligands L. In an example, solvent-free reaction of 10 mmol of tris(acetylacetonato)iridium with 60 mmol of 1-(1,1,2,2,3,3-tetramethyl-5-indanyl)isoquinoline for 100 h at 230° gave the invented complex (1a, shown as I) with 42% yield. In another example, test electroluminescent device, manufactured according to standard procedure with a light-emitting layer doped with 5% of the complex 1a exhibited electroluminescence with external quantum efficiency of 15.5% at 1000 cd/m2 at working voltage of 3.0 V with CIE(x,y) coordinates of 0.68,0.32 featuring lifetime of 18000 h. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Electric Literature of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Arnold, Lee D. et al. published their patent in 2021 |CAS: 39919-70-5

The Article related to peptidomimetic preparation viral cysteine protease inhibitor viral infection treatment, cysteine protease inhibitor antiviral sarscov2 covid19 mpro peptidomimetic preparation, covid19 treatment peptidomimetic preparation and other aspects.Synthetic Route of 39919-70-5

On October 21, 2021, Arnold, Lee D.; Lopatin, Uri; Keung, Walter published a patent.Synthetic Route of 39919-70-5 The title of the patent was Preparation of peptidomimetics as inhibitors of cysteine proteases for treatment of viral infections including COVID-19. And the patent contained the following:

The invention is related to the preparation of broad spectrum, viral protease inhibitor compounds, e.g., I, comprising a warhead covalently bound to a 3CL protease inhibitor, wherein the inhibitor compound covalently binds to Cys on the protease, and wherein the inhibitor compound is active against multiple such as viruses caliciviruses, picornaviruses and coronaviruses. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Thus, I was prepared by Ugi reaction between pyridine-3-carbaldehyde, 4-tert-butylaniline, (2R,4S)-1-tert-butoxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid and isocyanocyclohexane followed by cleavage of the tert-butoxycarbonyl group in II and treatment with BrCN. Select compounds of the invention were evaluated for their antiviral activity against COVID-19 (nCoV-2019, SARS-CoV2) Mpro in an enzymic assay and against human coronavirus 229E and OC43 in the cytopathic effect assays. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Synthetic Route of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Arnold, Lee D. et al. published their patent in 2021 |CAS: 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Kelly, Michael G. et al. published their patent in 2005 |CAS: 39919-70-5

The Article related to naphthyridinamine pyridopyrimidinamine preparation vanilloid receptor antagonist, ion channel ligand naphthyridinamine pyridopyrimidinamine preparation, pain inflammation traumatic injury drug naphthyridinamine pyridopyrimidinamine preparation and other aspects.Related Products of 39919-70-5

On July 21, 2005, Kelly, Michael G.; Janagani, Satyanarayana; Wu, Guoxian; Kincaid, John; Lonergan, David; Fang, Yunfeng; Wei, Zhi-Liang published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of bicycloheteroarylamines like 2,6-naphthyridinamines and pyrido[3,4-d]pyrimidinamine as ion channel ligands and uses thereof. And the patent contained the following:

Amine compounds (shown as I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; and stereoisomers and tautomers thereof; variables defined below; e.g. 7-(3-chloropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine (shown as II)) that are VR1 (VR = vanilloid receptor) antagonists are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of nonlimiting example, pain, inflammation, traumatic injury, and others. Compounds I are considered to be particularly beneficial as VR1 antagonists as certain compounds exhibit improved aqueous solubility and metabolic stability. For I: A and B = CH2, CR2’R2′, CO, CS and NR2′; Y = CH2, CR2’R2′ and NR2′; W and Z = CR4 and N, provided that W and Z both can not be N; R1 = (un)substituted aliphatic, alkyl, heteroalkyl, acyl, aryl, heteroaryl, aralkyl, heteroalkyl; each of R2 and R2′ = H, or (un)substituted C1-C6 alkyl, C1-C6 cycloalkyl, aryl and aralkyl; R3 = (un)substituted C1-C6 alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, bicycloalkyl, bicycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, and bicycloheteroaryl ring. R4 = H, or (un)substituted alkyl, (un)substituted acyl, (un)substituted acylamino, (un)substituted alkylamino, (un)substituted alkylthio, (un)substituted alkoxy, (un)substituted alkoxycarbonyl, (un)substituted alkylarylamino, (un)substituted arylalkyloxy, amino, (un)substituted aryl, arylalkyl, (un)substituted sulfoxide, (un)substituted sulfone, (un)substituted mercapto, (un)substituted aminosulfonyl, (un)substituted arylsulfonyl, sulfuric acid, sulfuric acid ester, (un)substituted dihydroxyphosphoryl, (un)substituted aminodihydroxyphosphoryl, azido, carboxy, (un)substituted carbamoyl, carboxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl, (un)substituted dialkylamino, halo, heteroaryloxy, (un)substituted heteroaryl, (un)substituted heteroalkyl, hydroxy, nitro, and thio. Although the methods of preparation are not claimed, 62 example preparations are included. For example, II was prepared in 5 steps (90, 38, 91, 87, 26 % yields) starting from 1-benzyl-3-(ethoxycarbonyl)-4-piperidone hydrochloride, formamidine acetate and NaOMe/MeOH and involving intermediates 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one, 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 7-benzyl-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine, and N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine. VR1 antagonist activity for 62 examples of I, capsaicin-induced VR1 current inhibition activity for 16 examples of I, reversal of thermal hyperalgesia in rats by II, pharmacokinetic profiles for 5 examples of I and plasma protein binding ability by II are reported. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Rai, Roopa et al. published their patent in 2022 |CAS: 39919-70-5

The Article related to pyrrolopyridine carboxamide derivative preparation inhalant formulation, hydroxyprostaglandin dehydrogenase inhibitor preparation pulmonary fibrosis copd, benzimidazole azabenzimidazole indole benzoxazine carboxamide preparation prostaglandin inhibitor and other aspects.COA of Formula: C9H14N2

On April 21, 2022, Rai, Roopa; Booth, Robert published a patent.COA of Formula: C9H14N2 The title of the patent was Preparation of 1H-pyrrolo[2,3-b]pyridine derivatives as PGDH inhibitors and inhalation formulations thereof. And the patent contained the following:

Disclosed are compounds that inhibit 15-hydroxy-prostaglandin dehydrogenase (PGDH) thus modulating prostaglandin levels which may be useful for the treatment of respiratory disorders such as COPD and idiopathic pulmonary fibrosis. Compounds of formula I [wherein R1 = (un)substituted C6-10aryl and 5- to 10-membered heteroaryl; R2 = H and R3 = CF3; R2 and R3 together = O; each R4 and R5 independently = halo, OH and derivatives, NH2 and derivatives, etc.; m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n = 1, 2, 3, or 4; p = 0, 1, 2, or 3] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compound II was prepared from a multistep procedure (preparation given). Exemplified I were evaluated for PGDH inhibitory activity from which II demonstrated an IC50 of < 0.1μM. In some embodiments, the compounds disclosed herein are formulated for delivery via inhalation. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).COA of Formula: C9H14N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem